A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

October 8, 2021

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

LY3209590

Administered SC

DRUG

Insulin Degludec

Administered SC

Trial Locations (64)

1407

CEMEDIC, Buenos Aires

2000

Instituto Médico Catamarca, Rosario

15401

Preferred Primary Care Physicians, Uniontown

20852

Endocrine and Metabolic Consultants, Rockville

22607

Diabeteszentrum Hamburg West, Hamburg

23758

RED-Institut GmbH, Oldenburg in Holstein

30291

Rophe Adult and Pediatric Medicine, Union City

33024

ALL Medical Research, LLC, Cooper City

33135

Suncoast Research Group, Miami

33312

Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care, Fort Lauderdale

34652

Suncoast Clinical Research, New Port Richey

35660

Syed Research Consultants Llc, Sheffield

37620

Holston Medical Group, Bristol

39120

SMO.MD GmbH, Magdeburg

39157

Sky Clin Resch - Quinn HC, Ridgeland

40213

L-MARC Research Center, Louisville

44869

Diabetes- und Stoffwechselpraxis Bochum, Bochum

45136

InnoDiab Forschung Gmbh, Essen

48145

Institut für Diabetesforschung GmbH Münster, Münster

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

58104

Lillestol Research LLC, Fargo

66299

Practice Dr.med. Denger and Dr.med. Pfitzner, Friedrichsthal

66606

Cotton O'Neil Diabetes and Endocrinology Center, Topeka

73069

Intend Research, LLC, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Dallas Diabetes Research Center, Dallas

77040

Juno Research, Houston

77074

Juno Research - Gessner, Houston

78231

Consano Clinical Research, LLC, Shavano Park

83221

Elite Clinical Trials, Blackfoot

83404

Rocky Mountain Clinical Research, Idaho Falls

83440

Elite Clinical Trials, Rexburg

90057

National Research Institute - Wilshire, Los Angeles

90242

Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz

90255

National Research Institute - Huntington Park, Huntington Park

91763

Catalina Research Institute, LLC, Montclair

91978

Encompass Clinical Research, Spring Valley

98057

Rainier Clinical Research Center, Renton

06708

CMR of Greater New Haven, Waterbury

33165 3338

New Horizon Research Center, Miami

78731-4309

Texas Diabetes & Endocrinology, P.A., Austin

C1120AAC

Centro Médico Viamonte, CABA

C1179AAB

Investigaciones Medicas Imoba Srl, CABA

C1180AAX

Fundacion Sanatorio Guemes, CABA

C1405BUB

Consultorio de Investigación Clínica EMO SRL, Caba

C1425DES

CEDIC, CABA

C1419AHN

Asociación de Beneficencia Hospital Sirio Libanés, Buenos Aires

C1204AAD

Instituto Centenario, Ciudad Autonoma de Buenos Aire

X5008HHW

Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Córdoba

T4000IHE

Clínica Mayo, San Miguel de Tucumán

01796

Private Practice - Dr. Christine Kosch, Pirna

31-261

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET, Krakow

02-117

Instytut Diabetologii Sp. z o.o, Warsaw

80-546

Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk

41-709

NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki, Ruda Śląska

82-300

Centrum Kliniczno-Badawcze, Elblag

20-333

Gabinety TERPA, Lublin

60-111

OMEDICA Medical Center, Poznan

61-655

Praktyka Lekarska, Poznan

33-122

Poradnia Chorob Metabolicznych, Wierzchosławice

50-127

NZOZ Regionalna Poradnia Diabetologiczna, Wroclaw

00717

Research and Cardiovascular Corp., Ponce

00917

GCM Medical Group, PSC - Hato Rey Site, San Juan

00767

Centro Profesional de Endocrinologia del Este, Yabucoa

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04450394 - A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter